Dexamethasone intravitreal implant (Ozurdex, Dexamethasone intravitreal implant in applicator) is a system that delivers a sustained release formulation of dexamethasone to the posterior segment of the eye. Dexamethasone is a corticosteroid which has anti- inflammatory and anti-vascular endothelial growth factor (VEGF) properties 4. Dexamethasone intravitreal implant is intended to replace current localised treatments and is administered by intravitreal injection every 6 months. One implant contains 700?g of dexamethasone 5.
Clobetasol propionate ophthalmic nanoemulsion is in development for the treatment of post-operative pain or inflammation following cataract surgery. A cataract is a cloudy area in the lens, which can develop slowly and progress to general loss of transparency, which may lead to functional impairment and visual deterioration. Cataract surgery is the only effective treatment to improve or maintain vision, however, inflammation and pain are common difficulties following this treatment.